Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylat...

Full description

Saved in:
Bibliographic Details
Main Authors CURTISS, DARIN THOMAS, YOO, JESSE I, GHANEKAR, AVANTI ARVIND, O'BERRY, ANTHONY RAY, IRWIN-PACK, KIM REES, PATEL, SAMIR MAGANBHAI, PAKOLA, STEPHEN JOSEPH, VAN EVEREN, SHERRI
Format Patent
LanguageChinese
English
Published 16.06.2021
Subjects
BANDAGES, DRESSINGS OR ABSORBENT PADS
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS
ENZYMOLOGY
FILTERS IMPLANTABLE INTO BLOOD VESSELS
FIRST-AID KITS
FOMENTATION
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
PROSTHESES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
TREATMENT OR PROTECTION OF EYES OR EARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.
Bibliography:Application Number: TW20209129003